United Therapeutics (NASDAQ:UTHR) CEO Sells $1,696,240.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $424.06, for a total value of $1,696,240.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $55,127.80. The trade was a 96.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Up 9.6%

UTHR opened at $455.32 on Thursday. The stock has a fifty day moving average of $404.55 and a 200-day moving average of $336.05. The firm has a market capitalization of $20.54 billion, a P/E ratio of 17.77, a PEG ratio of 4.53 and a beta of 0.66. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $479.50.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the prior year, the company earned $6.39 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Oppenheimer raised their target price on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Wednesday. UBS Group raised their target price on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a report on Monday, September 29th. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday. Finally, Royal Bank Of Canada assumed coverage on United Therapeutics in a report on Friday, September 26th. They set an “outperform” rating and a $569.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $462.54.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. F m Investments LLC grew its position in shares of United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 33 shares during the last quarter. HB Wealth Management LLC grew its position in shares of United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares during the last quarter. Hohimer Wealth Management LLC grew its position in shares of United Therapeutics by 0.3% in the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock valued at $3,900,000 after purchasing an additional 37 shares during the last quarter. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Park Avenue Securities LLC grew its position in shares of United Therapeutics by 1.7% in the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after purchasing an additional 39 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.